Latest news
Outpatient Bispecific Antibodies: Considerations for Step-Up Dosing, CRS, and ICANS - OncodailyOncodaily · Sat, 08 Aug 2026 09:01:53 GMTWhy CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma - CancerNetworkCancerNetwork · Fri, 07 Aug 2026 15:09:51 GMTThe Impact of Bispecifics in Community Oncology Settings - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 19:59:43 GMTThe Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials? - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 19:09:04 GMTAdverse Event Management for Bispecific Antibodies and CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 12:42:09 GMTREMS Programs for BCMA-Directed Therapies: Background, Best Practices, and Institutional Protocols - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 12:42:09 GMTContext scraps bispecific T-cell engager program to extend cash runway deeper into 2027 - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 09:55:15 GMTTargeted myeloma treatment shows promise in Phase 1 trial - Rare Cancer NewsRare Cancer News · Thu, 06 Aug 2026 07:00:00 GMT